Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus

Stittelaar, Koert J.; Amerongen, Geert van; Kondova, Ivanela; Kuiken, Thijs; Lavieren, Rob F. van; Pistoor, F.H.M.; Niesters, Hubert G. M.; Doornum, Gerard van; Zeijst, Bernard A.M. van der; Mateo, Luis; Chaplin, Paul; Osterhaus, Albert D. M. E.

doi:10.1128/jvi.79.12.7845-7851.2005

Cited by 208 publications

(173 citation statements)

References 22 publications

(27 reference statements)

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…This result, coupled with our findings, may provide an impetus for the reporting of macaque origins in pathogenesis studies and spur research into the functional consequences of these regional differences. Currently, macaque origins are rarely specified in methods sections of immunology and pathogenesis publications (42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54), though this data may be profoundly influential.…”

Section: Discussionmentioning

confidence: 99%

Unusually High Frequency MHC Class I Alleles in Mauritian Origin Cynomolgus Macaques

Krebs

Jin

Rudersdorf

et al. 2005

The Journal of Immunology

106

116

View full text Add to dashboard Cite

Acute shortages of Indian origin Rhesus macaques significantly hinder HIV/AIDS research. Cellular immune responses are particularly difficult to study because only a subset of animals possess MHC class I (MHC I) alleles with defined peptide-binding specificities. To expand the pool of nonhuman primates suitable for studies of cellular immunity, we defined 66 MHC I alleles in Cynomolgus macaques (Macaca fascicularis) of Chinese, Vietnamese, and Mauritian origin. Most MHC I alleles were found only in animals from a single geographic origin, suggesting that Cynomolgus macaques from different origins are not interchangeable in studies of cellular immunity. Animals from Mauritius may be particularly valuable because >50% of these Cynomolgus macaques share the MHC class I allele combination Mafa-B*430101, Mafa-B*440101, and Mafa-B*460101. The increased MHC I allele sharing of Mauritian origin Cynomolgus macaques may dramatically reduce the overall number of animals needed to study cellular immune responses in nonhuman primates while simultaneously reducing the confounding effects of genetic heterogeneity in HIV/AIDS research.

show abstract

Section: Discussionmentioning

confidence: 99%

Unusually High Frequency MHC Class I Alleles in Mauritian Origin Cynomolgus Macaques

Krebs

Jin

Rudersdorf

et al. 2005

The Journal of Immunology

106

116

View full text Add to dashboard Cite

show abstract

“…Immunodeficient mice given a single dose of MVA survived intranasal challenge with vaccine virus strain Western Reserve (WR) [3] and animals administered intracranial injections of MVA experienced minimal encephalopathic responses [4,5]. MVA was efficacious in animal variola challenge models [6,2] and protected monkeys against a lethal monkeypox challenge [7,8].…”

Section: Introductionmentioning

confidence: 99%

Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge

Frey

Newman

Kennedy

et al. 2007

Vaccine

109

115

View full text Add to dashboard Cite

Smallpox vaccination with replication deficient vaccinia strains such as Modified Vaccinia-Ankara (MVA) may induce protective immunity with improved safety and tolerability profiles compared with currently available smallpox vaccines. Ninety subjects were randomized equally to 6 groups in a partially blinded, randomized control clinical trial. IMVAMUNE ® (MVA-BN ® , Bavarian Nordic A/S, Kvistgård, Denmark) vaccine or placebo was administered at Study Day 0 and 28 by subcutaneous or intramuscular injection and five groups were challenged with Dryvax ® at study Day 112. Vaccination with two doses of IMVAMUNE ® was safe and well-tolerated compared to Dryvax ® . IMVAMUNE ® produced comparable cellular and humoral immune responses to one dose of Dryvax ® and the immunity induced appears robust 90 days post vaccination by evidence of attenuated primary cutaneous reaction responses following Dryvax ® . IMVAMUNE ® vaccination prior to Dryvax ® reduced virus replication at the Dryvax ® site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response. MO 63110,, E-mail address: E-mail: freyse@slu.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In a recent study, IMVAMUNE ® , a highly attenuated vaccinia strain derived from MVA-572 (obtained from Dr. Anton Mahr), does not replicate in human cells and was safe and immunogenic in humans [9]. The present study sought to evaluate the safety and immunogenicity of a range of doses and routes of administration of IMVAMUNE ® . Potential surrogate efficacy of MVA-induced immune responses was evaluated by the ability of two doses of IMVAMUNE ® to reduce the clinical effects of a Dryvax ® challenge. Keywords NIH Public Access Author Manuscript Methods Vaccines and DiluentsIMVAMUNE ® (Bavarian Nordic A/S, Kvistgård, Denmark), a modified vaccinia Ankara vaccine (lot no. 130303), is a non-replicating virus in human cells used as the MVA smallpox vaccine in this study. Lyophilized vaccine was reconstituted with sterile water for injection (WFI) (Impfstoffwerk Dessau-Thornau GmbH, Germany). The reconstituted vaccine contains approximately 2 × 10 8 TCID 50 per ml. The placebo was sterile saline for injection (American Regent Laboratories, Inc, Shirley, NY). Licensed smallpox vaccine (Dryvax ® , Wyeth Laboratories, Marietta, PA) (lot no. 4008284), a replicating vaccinia virus provided by the Centers for Disease Control and Prevention in Atlanta, GA, was used as both the comparator vaccine and the virus in the challenge portion of this study.Reconstituted IM...

show abstract

“…At present two NHP models are established. These are MPXV infection of cynomolgus macaques (Macaca fascicularis) (Hooper et al, 2004) and rhesus macaques (Macaca mulatta) (Stittelaar et al, 2005) as well as VARV infection of cynomolgus macaques .…”

Section: Introductionmentioning

confidence: 99%

The Pathology of Experimental Poxvirus Infection in Common Marmosets (Callithrix jacchus): Further Characterization of a New Primate Model for Orthopoxvirus Infections

Mätz‐Rensing

Stahl–Hennig∥

Kramski

et al. 2012

Journal of Comparative Pathology

View full text Add to dashboard Cite

show abstract

Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus

Cited by 208 publications

References 22 publications

Unusually High Frequency MHC Class I Alleles in Mauritian Origin Cynomolgus Macaques

Unusually High Frequency MHC Class I Alleles in Mauritian Origin Cynomolgus Macaques

Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge

The Pathology of Experimental Poxvirus Infection in Common Marmosets (Callithrix jacchus): Further Characterization of a New Primate Model for Orthopoxvirus Infections

Contact Info

Product

Resources

About